The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Scientific considerations for the regulatory evaluation of cell therapy products
Abstract
Cell therapy involves the administration of a viable somatic cell preparation to a patient for the treatment of a disease or traumatic damage. Because cell therapies are complex and very different from traditional biological products, they present significant challenges for regulatory authorities, manufacturers, developers, health care providers, and patients involved in their application. Like other emerging areas of biomedical research and development, there are many issues where regulatory views and decisions among countries and regions may differ due to minimal scientific evidence to support safety and efficacy, and lack of experience with these novel treatments. A brief overview of the current regulatory landscape for cell-based therapies is presented, and the need for a global effort to develop a set of common principles that may serve to facilitate the regulatory evaluation and market availability of these products is identified. In addition, a number of elements that could form a core consensus package of requirements for evaluating human cell therapy products is presented in the supplemental material which should be read in conjunction with the manuscript.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“although it is important to bear in mind that cells from other species can also harbor serious human pathogens (Stacey, 2007; Mahy et al., 1991; Petricciani et al., 2017).”
From Guidance document on Good cell and tissue culture practice 2.0 (GCCP 2.0) (2021) · cites this paper as Petricciani et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300313 · Cited by 371
Self-citationConsensus Guidance for Banking and Supply of Human Embryonic Stem Cell Lines for Research Purposes
Initiative, T. I. S. C. B. (2009) · Stem Cell Reviews and Reports · doi:10.1007/s12015-009-9085-x · Cited by 162
Good Cell Culture Practice for stem cells and stem-cell-derived models
Pamies, D. (2016) · ALTEX · doi:10.14573/altex.1607121 · Cited by 160
Andrews, P., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Br…#x00FC;stle, O., Choi, M., Choi, Y.-M., Crook, J., de Sousa, P., et al. (2015) · Regenerative Medicine · doi:10.2217/rme.14.93 · Cited by 113
Self-citationHayakawa, T., Aoi, T., Umezawa, A., Ozawa, K., Sato, Y., Sawa, Y., Matsuyama, A., Yamanaka, S., & Yamato, M. (2015) · Regenerative Therapy · doi:10.1016/j.reth.2015.05.002 · Cited by 37
Self-citationHayakawa, T., Aoi, T., Umezawa, A., Ozawa, K., Sato, Y., Sawa, Y., Matsuyama, A., Yamanaka, S., & Yamato, M. (2015) · Regenerative Therapy · doi:10.1016/j.reth.2015.06.004 · Cited by 28
Self-citationHayakawa, T., Aoi, T., Umezawa, A., Ozawa, K., Sato, Y., Sawa, Y., Matsuyama, A., Yamanaka, S., & Yamato, M. (2015) · Regenerative Therapy · doi:10.1016/j.reth.2015.06.002 · Cited by 27
Self-citationTumorigenicity assessment of human cell-processed therapeutic products
Yasuda, S., & Sato, Y. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.05.008 · Cited by 22
Hayakawa, T., Aoi, T., Umezawa, A., Ozawa, K., Sato, Y., Sawa, Y., Matsuyama, A., Yamanaka, S., & Yamato, M. (2015) · Regenerative Therapy · doi:10.1016/j.reth.2015.06.001 · Cited by 22
Self-citationHayakawa, T., Aoi, T., Umezawa, A., Ozawa, K., Sato, Y., Sawa, Y., Matsuyama, A., Yamanaka, S., & Yamato, M. (2015) · Regenerative Therapy · doi:10.1016/j.reth.2015.05.001 · Cited by 20
Self-citation
Research works printed but not linked: 3
- 2007, Regulation (EC) No 1394/2007 of the European parliament and of the council on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) No 726/2004, OJ, L324, 121e37
- 2001, Directive (EC) 2001/83 of the European Parliament and of the Council on the Community code relating to medicinal products for human use, OJ, L311, 67
- 2004, Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ, L102, 48e58
Cited by
Next-generation stem cells — ushering in a new era of cell-based therapies
Kimbrel, E. A., & Lanza, R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0064-x · Cited by 275
Guidance document on Good cell and tissue culture practice 2.0 (GCCP 2.0)
Pamies, D. (2021) · ALTEX · doi:10.14573/altex.2111011 · Cited by 100
Metadata
- Authors
- Petricciani, J., Hayakawa, T., Stacey, G., Trouvin, J.-H., & Knezevic, I.
- Venue
- Biologicals
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 50
- Pages
- 20-26
- ISSN
- 1045-1056
- Cited by
- 49
- References
- 20
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scientific considerations for the regulatory evaluation of cell therapy products. https://app.cochat.ai/papers/10.1016/j.biologicals.2017.08.011
- The paper
- Petricciani, J., Hayakawa, T., Stacey, G., Trouvin, J.-H., & Knezevic, I. (2017). Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals. https://doi.org/10.1016/j.biologicals.2017.08.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.